• Explore /
  • Poster
  • / Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.

Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.

Abstract Video & Slides Poster

Authors

Francesco Passamonti

Francesco Passamonti

Department of Medicine and Surgery, University of Insubria, Varese, Italy

Francesco Passamonti , James M. Foran , Anand Tandra , Valerio De Stefano , Maria Laura Fox , Ahmad Hatem Mattour , Mary Frances McMullin , Andrew Perkins , Gabriela Rodriguez-Macias , Hassan Sibai , Qin Q. Qin , Jalaja Potluri , Jonathan B. How

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT03222609

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7015)

DOI

10.1200/JCO.2022.40.16_suppl.7015

Abstract #

7015

Poster Bd #

246

Abstract Disclosures

Similar Posters

First Author: Haris Ali

First Author: Ruben A. Mesa

First Author: Lucia Masarova

First Author: Aaron Thomas Gerds